Get the Stockscreener App
4.80
0.84%
0.04
Pre-market:
4.88
0.08
+1.67%
Agenus Inc stock is traded at $4.80, with a volume of 605.53K.
It is up +0.84% in the last 24 hours and down -1.23% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$4.76
Open:
$4.75
24h Volume:
605.53K
Relative Volume:
0.49
Market Cap:
$131.60M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0698
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
-10.45%
1M Performance:
-1.23%
6M Performance:
+37.14%
1Y Performance:
-9.09%
1-Day Range:
$4.60
$4.82
1-Week Range:
$4.60
$5.5896
52-Week Range:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
4.80 | 130.50M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Is Agenus Inc. exposed to currency risksHigh Profit Stock Recommendations - kangso.co.kr
Agenus Earnings Outlook: Analysts Expect $0.50 EPS in Q2 2025 - AInvest
Can Agenus Inc. disrupt its industryHyper-Growth Screener - mustnews.co.kr
Agenus AGEN Q2 2025 Earnings Preview Upside Potential on Strategic CDMO Shift - AInvest
Examining the Future: Agenus's Earnings Outlook - 富途牛牛
Should value investors consider Agenus Inc.ROI Enhanced Trading Plan - newsyoung.net
Smart tools for monitoring Agenus Inc.’s price actionLong Term Stock Growth Plan Suggestions - Newser
Why Agenus Inc. stock attracts strong analyst attentionInsider Strategy for High Conviction Picks - Newser
Tools to monitor Agenus Inc. recovery probabilityLong-Term Stock Growth Forecast Insights - Newser
Agenus Inc. shares fall 2.41% intraday after Delhi High Court restrains Zydus Lifesciences from launching nivolumab biosimilar. - AInvest
How many analysts rate Agenus Inc. as a “Buy”Build a portfolio that outperforms the market - Jammu Links News
What institutional investors are buying Agenus Inc. stockMaximize portfolio value with expert tips - Jammu Links News
Agenus Inc. Stock Analysis and ForecastMaximize returns with strategic portfolio planning - Jammu Links News
Is Agenus Inc. a growth stock or a value stockAchieve superior returns through strategic trading - Jammu Links News
What markets is RILYL expanding into Is Agenus Inc. stock a good long term investment optionConsistently high yield - Jammu Links News
Why is Agenus Inc. stock attracting strong analyst attentionExceptional trading results - Jammu Links News
What makes Agenus Inc. stock price move sharplyCapitalize on proven investment strategies - Jammu Links News
Should I hold or sell Agenus Inc. stock in 2025Discover stocks with explosive potential - Jammu Links News
What analysts say about Agenus Inc. stockMaximize returns with strategic trading plans - Jammu Links News
How strong is Agenus Inc. company’s balance sheetAchieve rapid portfolio growth with expert guidance - Jammu Links News
Is Agenus Inc. a good long term investmentRapid wealth creation - Jammu Links News
What is the dividend policy of Agenus Inc. stockHigh-velocity capital appreciation - Jammu Links News
What are the latest earnings results for Agenus Inc.Consistently profitable trades - Jammu Links News
What are analysts’ price targets for Agenus Inc. in the next 12 monthsMarket-beating returns - Jammu Links News
Statistical indicators supporting Agenus Inc.’s strengthRetirement Investment Outlook and Return Summary - Newser
Agenus Announces Q2 2025 Financial Results, Stakeholder Briefing to Highlight Botensilimab and Balstilimab Programs - AInvest
Is Agenus Inc. stock overvalued or undervaluedEarnings Report Alerts To Watch Now - Jammu Links News
Zacks.com featured highlights include QuantumScape, Civeo and Agenus - The Globe and Mail
QuantumScape, Civeo, and Agenus Lead the Way in Earnings Acceleration - AInvest
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report - The Globe and Mail
Agenus Inc. shares rise 2.90% after-hours after announcing Q2 2025 financial results and strategic update. - AInvest
Leading vs lagging indicators on Agenus Inc. performanceAlpha Stock Picks with Chart Confirmation - Newser
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - Benzinga
Agenus Inc. Company’s Quarterly Earnings Growth: What the Numbers SayLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Agenus Inc. to Host Earnings Call - ACCESS Newswire
Traders Watching For Reversal Pattern in Agenus Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
Agenus Inc. Bounces Off Moving Average SupportEarly Entry Picks Before News Breakout Reviewed - metal.it
RSI Crosses Above 30 for Agenus Inc. — Reversal in SightFast Return Equity Trade Forecast Points to Small Caps - metal.it
Agenus Inc. Breaks Losing Streak — Is the Trend ReversingAI Forecast for Trending Stocks Indicates Upside - beatles.ru
What are the technical indicators suggesting about Agenus Inc.Build a diversified portfolio for stability - Jammu Links News
Will Agenus Inc. continue its uptrendHigh Yield Watchlist with Filtered Picks - Newser
What are Agenus Inc. company’s key revenue driversExponentially increasing returns - jammulinksnews.com
What markets is Agenus Inc. expanding into Is GDXU stock a good long term investment optionExplosive earning power - Jammu Links News
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):